Generics Industry News Search
 |
|
|
|
|
|
|
March 2005 News Archive |
|
|
| |
|
MIAMI - March 1, 2005 - IVAX Corporation (AMEX: IVX, LSE: IVX.L, WSE: IVX) has received a final approval from the U.S. Drug and Food Administration (FDA) for its Abbreviated New Drug Application (ANDA) for cilostazol tablets, 100 mg This product will be sold through the company's wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Cilostazol tablets, 100 mg is the generic equivalent of Pletal® Tablets, which is marketed by Otsuka American Pharmaceutical, Inc. for intermittent claudication (pain in the legs that happens when walking and goes away with rest). According to IMS data, U.S. sales of cilostazol tablets, 100 mg were $154.2 million for 2004....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
HAYWARD, Calif.--(BUSINESS WIRE)--March 2, 2005--IMPAX Laboratories, Inc. (NASDAQ:IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval to the Company's Abbreviated New Drug Application for a generic version of Dantrium(R) (Dantrolene Sodium) 25, 50 and 100 mg Capsules....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
HAYWARD, Calif.--(BUSINESS WIRE)--March 3, 2005--IMPAX Laboratories, Inc. (NASDAQ:IPXL) has begun commercial distribution of its generic version of OxyContin(R) (Oxycodone Hydrochloride) Controlled Release 80 mg Tablets. ...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
HAYWARD, Calif.--(BUSINESS WIRE)--March 9, 2005--IMPAX Laboratories, Inc. (NASDAQ:IPXL) today announced that Biovail Laboratories Inc., a subsidiary of Biovail Corporation (NYSE:BVF) (TSX:BVF), has filed a lawsuit against the Company in the United States District Court, Eastern District of Pennsylvania (Philadelphia), alleging patent infringement related to IMPAX's filing for a generic version of Wellbutrin XL(R). ...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
WOODCLIFF LAKE, N.J., March 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that Kos Pharmaceuticals, Inc. (Nasdaq: KOSP) has filed a motion for a temporary restraining order and a preliminary injunction in the United States District Court for the Southern District of New York seeking to prevent Barr from launching generic versions of Kos' Niaspan(R) 500 mg, 750 mg and 1000 mg Extended-Release Tablets (Niacin Extended-Release Tablets) following final U.S. Food & Drug Administration (FDA) approval....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Zydus Cadila's US subsidiary, Zydus Pharmaceuticals (USA) Inc. has entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare and one of the top ten Generics companies in the US....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
AstraZeneca today announced that the European Patent Office (EPO) has ruled that the European combination patent for Symbicort® is still valid, despite a challenge by several generic manufacturers....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
PARIS, March 11 /CNW Telbec/ - Sanofi-aventis has learned through the Canadian Ministry of Health website that Novopharm Limited had obtained marketing approval in Canada for a product claiming to be generic enoxaparin.
Sanofi-aventis companies Aventis Pharma Inc. and Aventis Pharma S.A. are bringing suit in the Federal Court against Novopharm for patent infringement of Canadian patent 2045433, which covers Lovenox(R). Sanofi-aventis will vigorously defend its legal rights with respect to this patent....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
The Chennai-based global pharma major, Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), today announced that it has entered into an exclusive agreement with STADA Pharmaceuticals, Inc. (STADA), the U.S. subsidiary of STADA Arzneimittel AG, for the development and supply of six prescription generic drug products to STADA for the US market. ...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Jerusalem, Israel, February 17, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has settled patent litigation with GlaxoSmithKline relating to lamotrigine, the generic version of GlaxoSmithKline's Lamictal®....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Creates global provider of generic prescription drugs, active pharmaceutical ingredients and consumer healthcare products . ALLEGAN, Mich. - March 17, 2005 - The Perrigo Company (Nasdaq: PRGO) today announced the completion of its acquisition of Agis Industries (1983) Ltd., a developer and manufacturer of specialized generic pharmaceuticals and active pharmaceutical ingredients (API)....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
MIAMI - March 23, 2005 - IVAX Corporation (AMEX: IVX, LSE: IVX.L, WSE: IVX) launched its AB-rated gabapentin capsules in 100 mg, 300 mg and 400 mg dosage strengths. Gabapentin is the generic equivalent of Neurontin® a drug used to treat epileptic seizures which is marketed by Warner-Lambert, a unit of Pfizer Inc. According to IMS data, for the fourth quarter 2004, U.S. sales of Neurontin® and gabapentin in 100, 300 and 400 mg dosage strengths were $337 million. ...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Jerusalem, Israel, February 24, 2005 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Methylprednisolone Acetate Injectable Suspension, 40 mg/mL and 80 mg/mL in single dose vials....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Jerusalem, Israel, March 27, 2005 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Amlodipine Besylate Tablets, 2.5 mg, 5 mg and 10 mg. ...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
March 28, 2005: Glenmark Pharmaceuticals Ltd and Shasun Chemicals and Drugs Ltd have entered into a collaboration agreement for the joint development, filing and marketing of twelve generic pharmaceutical products for the US market. The product list includes a mixture of off-patent and patent-protected molecules with cumulative annual sales in the US of about USD 8 Bn....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
Dr. Reddy's unique initiative to partner with India's largest private equity investor for pipeline expansion for the U.S. Generics market.
Dr. Reddy's to leverage global scale and infrastructure for pipeline expansion....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
New Delhi - March 29, 2005. Ranbaxy Laboratories Ltd (Ranbaxy) today announced that it successfully invalidated claims 1-3 (all claims sought to be invalidated) of Austrian Patent No. AT E 207 896 as anticipated by, and as lacking inventive step over, respectively, a Pfizer-owned published patent application and a Pfizer owned patent, as reflected by a decision released by the Austrian Patent Office....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
WOODCLIFF LAKE, N.J., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Berlex Laboratories, Inc., a U.S. affiliate of Schering AG, Germany in connection with Berlex's Yasmin(R) (drospirenone and ethinyl estradiol) oral contraceptive. Yasmin is a low-dose, monophasic oral contraceptive and the first birth control pill to contain the progestin, drospirenone....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
PITTSBURGH, March 29 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths. Olanzapine Tablets are the generic version of Eli Lilly and Company's Zyprexa(R) Tablets, which has annual U.S. sales of approximately $2.8 billion....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
WOODCLIFF LAKE, N.J., March 30, 2005 /PRNewswire-FirstCall via COMTEX/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) and PLIVA d.d. (LSE: PLVD, ZSE: PLVA-R-A) today announced that Barr's subsidiary, Barr Laboratories, Inc., and PLIVA's subsidiaries, PLIVA Croatia Ltd. and PAM Kft., have entered into a development, supply and marketing agreement for the generic biopharmaceutical Granulocyte Colony Stimulating Factor (G-CSF). ...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
Court Agrees to Discontinue Further Proceedings to Allow Parties to Negotiate Definitive Agreement
WOODCLIFF LAKE, N.J. and CRANBURY, N.J., March 30 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) and Kos Pharmaceuticals, Inc. (Nasdaq: KOSP) today announced that Barr Laboratories, Inc. and Kos are engaged in discussions to settle the outstanding patent litigation regarding Kos' Niaspan(R) product. ...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
New Delhi - March 30, 2005. Ranbaxy Laboratories Limited (Ranbaxy) announced today that the U.S. District Court for the District of New Jersey hearing the preliminary injunction motion brought by Pfizer against Teva Pharmaceuticals USA, Inc. (Teva) and Ranbaxy Pharmaceuticals Inc. (RPI) enjoined Teva and RPI from selling RPI's quinapril tablets (5, 10, 20, and 40 mg)....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
WOODCLIFF LAKE, N.J., March 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that the U.S. District Court for the Eastern District of New York has granted summary judgment in the Company's favor and rejected a challenge to the lawfulness of its 1997 settlement with Bayer Corporation of patent litigation related to the antibiotic Cipro(C). ...
|
| |
|
|
Read more >>
|
| |
|
|
|
|
|
Contribute
If you would like to contribute or publish your
company press releases at GenericsWeb, please
email us.
|
Home
